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Abstract
Tuberculosis remains a major public health concern in Russia and worldwide. Given the great geographical, ethnic, and socio-economic
heterogeneities between Russian regions, epidemiological data cannot be generalized from a regional to a country-wide level. We pres-
ent data on the epidemiology of tuberculosis in Central Russia. We report a high level of resistance to major antitubercular drugs in
both new and previously treated patients in the region. The level of drug resistance in new cases was almost twice as high as the esti-
mated average national level. The Mycobacterium tuberculosis strains that circulated in the region were predominantly represented by
LAM-RUS and Beijing genotypes. These two lineages were strongly associated with drug resistance and clustering. Using molecular epi-
demiology techniques, we showed a high interpenetration by M. tuberculosis strains between the prison and civilian populations. A lim-
ited number of identical strains were responsible for the majority of drug-resistant tuberculosis cases in both settings.
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Introduction
Tuberculosis (TB) is among the deadliest human diseases
worldwide, with more than 8 million new cases and approxi-
mately 1.6 million deaths being attributed to the disease every
year [1]. After a number of years of steady decline in TB inci-
dence, the last decade of the 20th Century showed a surge of
newly diagnosed cases in almost every country. Russia was
ranked twelfth in the list of the countries with high TB inci-
dence, with 107/100 000 new cases and 17/100 000 TB-
related deaths reported in 2006 [1]. Deterioration of the
healthcare system, lack of funds for active case ﬁnding, and an
occasional shortage of antitubercular drugs induced the two-
fold rise in TB incidence between 1994 and 2000. The
increase in the number of deaths and of patients who failed to
complete their treatment regimen was especially pronounced.
Together with the growing epidemic of HIV, tuberculosis
poses a serious public health threat in the Russian Federation.
One of the key factors hampering effective TB control mea-
sures is the prevalence of drug-resistant cases. Russia has one
of the highest relative incidences of multidrug-resistant infec-
tions (MDR-TB; i.e. resistant to at least isoniazid and rifampi-
cin) in the world [2]. Treatment of MDR-TB requires up to
2 years of therapy, using up to 100-fold more expensive treat-
ment regimens compared to nonresistant TB [3]. Second-line
drugs are usually less effective and poorly tolerated. The dura-
tion of treatment and the inclusion of injectable drugs makes
chemotherapy of MDR cases especially prone to non-adher-
ence and default. Several pilot studies of TB drug resistance to
a panel of antitubercular drugs showed a high prevalence of
resistance to both ﬁrst- and second-line drugs in Russia [4].
In the present study, we aimed to identify major Mycobacte-
rium tuberculosis strains that contributed to TB epidemics in
Central Russia before the introduction of the Directly
Observed Therapy Strategy (DOTS). The modiﬁed strategy
for TB treatment that included all the basic principles of
DOTS was adopted in the region in 2005. This paralleled a
noticeable decrease in TB incidence in the Tula region, from
94.9 to 77.7 new cases per 100 000 population between 2003
and 2007 [5]. In 2002, a total of 4299 TB patients, including
1666 newly diagnosed cases, were registered in the Tula
region. We present data on the prevalence of M. tuberculosis
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strains in the Tula area and estimate the rate of TB drug
resistance immediately before the DOTS era. Using molecu-
lar epidemiology methods, we have compared strains recov-
ered from patients in the Tula city TB clinic with those from
the Tula region prison hospital, as investigated previously [6].
We believe that the present study is a ﬁrst step towards
understanding the impact of DOTS on the diversity of
M. tuberculosis strains circulating in the region.
Materials and Methods
Patients
All culture-positive patients who were registered and
received treatment in the Tula regional TB clinic in 2001–
2002 were enrolled in the present study. Informed consent
was received from all patients and the study was approved
by the State Research Center for Applied Microbiology and
Biotechnology (SRCAMB) ethical committee. Limited demo-
graphic information about age, sex, employment and residen-
tial status, history of incarceration, and concomitant diseases
such as substance abuse, HIV and viral hepatitis status was
collected. Patients were divided into two groups: the ﬁrst
group comprised newly diagnosed sputum smear-positive
patients who had not received anti-TB medication previously,
or who had been treated for less than 1 month; the second
group consisted of smear-positive patients who had previ-
ously taken one or more drugs for more than 1 month.
Bacterial strains and drug susceptibility testing
Sputum samples were collected and initially cultured in the
Tula clinic. One isolate per patient was forwarded to
SRCAMB (unaccompanied by patient identiﬁers).
Isolates were cultivated on Lo¨wenstein–Jensen (LJ) med-
ium. The identiﬁcation of M. tuberculosis was conﬁrmed using
a combination of growth, macroscopic and microscopic
appearance, and biochemical characterization. The M. tuber-
culosis H37Rv strain was used as a reference for all microbio-
logical and molecular tests.
Susceptibility testing was performed by the absolute con-
centration method on LJ medium as described previously [7].
Resistance to pyrazinamide was not identiﬁed as a result of
the poor performance of the method on the LJ medium. Drug
concentrations were: 1 mg/L of isoniazid (INH), 5 mg/L of
streptomycin (STR), 30 mg/L of kanamycin (KAN), 2 mg/L of
ethambutol (EMB), and 20 mg/L of rifampicin (RIF).
DNA extraction and molecular tests
The genomic DNA was puriﬁed as described previously [8].
IS6110-restriction fragment length polymorphism (RFLP) was
performed according to the standard protocol [9]. Finger-
prints were scanned and analysed using GELCOMPAR II soft-
ware, version 2.5 (Applied Maths, St-Martens-Latem,
Belgium). Spoligotyping was performed as described previ-
ously [10].
Mutations in rpsL, in codons 300–500 of the katG, rifampin
resistance determining region of rpoB (codons 507–533), and
in two fragments of 16S rrna (positions 427–980 and 1288–
1543), were identiﬁed by sequencing. Identiﬁcation of muta-
tions in codons 306 and 406 of embB was carried out by the
allele-speciﬁc depletory PCR assay [11]. An in-house allele-
speciﬁc PCR assay for fast identiﬁcation of single nucleotide
polymorphism (SNP) clustered groups [12] was used (for
details, see Supporting Information). A variant of ligation-
mediated PCR [13] was used for identiﬁcation of the
insertion sites of IS6110 elements in the genomes of
M. tuberculosis clinical isolates (for protocol and sequences,
see Supporting Information).
Statistical analysis
IS6110-RFLP patterns identiﬁed in the present study were
compared with those reported previously [6]. In total, 322
IS6110-RFLP patterns from both settings were compared
by the unweighted pair group method with arithmetic
mean (2% band position tolerance) with Jaccard’s similarity
index.
Statistical calculations were performed using MATLAB 7.6
software (MathWorks, Inc., Natick, MA, USA). Fisher’s exact
test was used for calculation of p-values.
Results
Study population
The Tula regional tuberculosis outpatient clinic provides
healthcare to TB patients living in Tula city and the sur-
rounding suburbs. A total 648 TB patients received treat-
ment in the clinic during 2001–2002. All patients who had at
least one culture positive result during this period were
enrolled in the present study. Viable M. tuberculosis isolates
were recovered from 241 patients (37.2% recovery rate): 36
females and 205 males. The age range of patients was 15–
82 years (mean 44 years). Eighty-ﬁve (35.2%) M. tuberculosis
isolates were recovered from newly registered TB patients
and 156 (64.7%) were from previously treated patients.
Forty-one patients (17%) relapsed. One isolate per patient
was forwarded from the Tula clinic to SRCAMB for microbi-
ological analyses, drug susceptibility testing and genotyping.
The demographic and clinical characteristics of patients are
summarized in Table 1.
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Drug resistance proﬁles
The highest rate of drug resistance was observed for STR,
followed by RIF and INH for both new and previously trea-
ted case categories (Table 2). There were 28 monoresistant
strains: 17 STR-resistant, ﬁve RIF and four EMB-resistant,
one INH-resistant and one KAN-resistant. All but four
strains resistant to two or more drugs (153/157) were resis-
tant to STR. Forty-seven isolates (11.2%) were resistant to
four drugs, and 51 isolates (29.4%) were resistant to all ﬁve
drugs tested. The level of drug resistance was 15–25% lower
than that observed in the prison setting of our previous
investigaqtion [6] for all drug tested (Table 3). However, the
relative risk of acquiring MDR during treatment was similar:
2.24 (95% CI 1.46–3.65) for the prison and 2.74 (95% CI
1.86–4.13) for the civilian settings.
Mutations that conferred drug resistance were analysed
(Table 4). Eighty-three percent of RIF-resistant strains (116/
139) contained mutations in 81 nt RRDR of rpoB. One strain
contained an unusual 6 nt substitution in rpoB, resulting in
H526S and L527G amino acid replacement. Ninety percent
(123/136) of INH-resistant isolates carried either threonine
or arginine in codon 315 of katG. Kanamycin resistance was
a result of substitution in positions 1400 or 1401 of rrs. Point
mutations in positions 513 and 516 of rrs (40%, 68/170) and
in codons 43 and 88 of rpsL (31/170, 18.2%) were a major
cause of STR resistance.
Correlation of mutations in embB and clinical resistance to
ethambutol has been heatedly debated in recent literature
[14,15]. In the study sample, 93 strains (38.6%) contained
mutations in either the 306 or 406 codon of embB. Thirty-
six of 162 (22.2%) EMB-susceptible strains and 57 of 79
(72.2%) EMB-resistant strains carried mutant embB alleles.
This ratio may reﬂect difﬁculties in determining ethambutol
susceptibility on LJ medium.
Molecular epidemiology
Four of six M. tuberculosis SNP clustered groups (SCG) [12]
were present in the sample. Seventy-four isolates were mem-
bers of SCG2, 30 and 34 isolates were of SCG3 and SCG6,
respectively. SCG5 was the most populated group, with 103
members. A total of 49 spoligopatterns were identiﬁed,
including 17 orphans (i.e. those not listed in the SpolDB4
TABLE 1. Demographic and clinical characteristics of study
population
Parameter
New cases
(n = 85)
Previously treated
cases (n = 156)
Total
(n = 241)
Demographic
Female 17/85 (20%) 19/156 (12.2%) 36/241 (14.9%)
Homeless 3/85 (3.5%) 4/156 (2.6%) 7/241 (2.9%)
Unemployed 39/74 (52.7%) 65/135 (48.1%) 104/209 (49.8%)
Previous prisoners 16/83 (19.3%) 45/144 (31.2%) 61/227 (26.9%)
Alcohol abuse 42/85 (49.4%) 101/146 (69.2%) 143/231 (61.9%)
Nonresident in the
Tula region
6/85 (7.1%) 8/156 (5.1%) 14/241 (5.8%)
Clinical
Moderate focus TB 8/85 (9.4%) 6/144 (4.2%) 14/229 (6.1%)
Advanced cavitary
disease
11/85 (12.9%) 63/144 (43.7%) 74/229 (32.3%)
Smear positive 52/85 (61.2%) 121/140 (86.4%) 173/225 (76.9%)
Concomitant
extrapulmonary TB
5/85 (5.9%) 7/144 (4.9%) 12/229 (5.2%)
TB/HCV or 14/85 (16.5%) 11/144 (7.6%) 25/229 (10.9%)
TB/HBV co-infection 0/85 (0%) 2/156 (1.3%) 2/241 (0.8%)
TB, tuberculosis; HCV, hepatitis C virus; HBV, hepatitis B virus.
TABLE 2. Drug resistance in Mycobacterium tuberculosis clin-
ical isolates recovered from civilian patients divided by case
category
Drug
New cases
(n = 85)
Previously treated
cases (n = 156) OR (95% CI)
Susceptible 29 (34%) 27 (17%) 2.5 (1.4–4.5)
STR 49 (58%) 121 (78%) 0.4 (0.2–0.7)
RIF 31 (36%) 108 (69%) 0.3 (0.2–0.4)
INH 28 (33%) 108 (69%) 0.2 (0.1–0.4)
KAN 21 (25%) 81 (52%) 0.3 (0.2–0.5)
EMB 20 (24%) 59 (38%) 0.5 (0.3–0.9)
MDR 19 (22%) 95 (61%) 0.2 (0.1–0.3)
STR, streptomycin; RIF, rifampicin; INH, isoniazid; KAN, kanamycin; EMB, eth-
ambutol; MDR, multidrug-resistant.
TABLE 3. Differences in rates of resistance to ﬁrst line
drugs among civilian and prison cases
Drug
Civiliansa
(n = 241)
Prisonersb
(n = 87) OR (95% CI)
Susceptible 56 (23%) 8 (9%) 2.9 (1.3–6.3)
STR 170 (71%) 77 (89%) 0.2 (0.1–0.5)
RIF 139 (58%) 67 (77%) 0.4 (0.2–0.7)
INH 136 (56%) 67 (77%) 0.3 (0.2–0.6)
KAN 102 (42%) 58 (67%) 0.3 (0.2–0.6)
MDR 113 (47%) 62 (71%) 0.3 (0.2–0.6)
STR, streptomycin; RIF, rifampicin; INH, isoniazid; KAN, kanamycin; MDR, multi-
drug-resistant.
aPresent study.
bData from Ignatova et al. [6].
TABLE 4. Prevalence of mutant alleles in drug resistant
strains
Drug (total no.) Mutation
Number
of strains (%)
STR (n = 170) 513A>C rrs 60 (35%)
L43R rpsL 28 (17%)
Rare or unknown 82 (48%)
INH (n = 136) S315T katG 121 (89%)
Rare or unknown 15 (11%)
RIF (n = 139) D516V rpoB 65 (47%)
S531L rpoB 33 (24%)
Rare or unknown 41 (29%)
KAN (n = 102) 1400 A>G rrs 62 (61%)
Rare or unknown 40 (39%)
STR, streptomycin; RIF, rifampicin; INH, isoniazid; KAN, kanamycin.
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[16]). Two predominant spoligotypes were ST1 (Beijing) and
ST252 (LAM), represented by 58/241 and 55/241 isolates,
respectively. IS6110-RFLP patterns were identiﬁed for 234
isolates. Eight isolates (3.4%) had six or less IS6110 copies
per genome. One hundred and sixty unique and 23 clustered
IS6110 ﬁngerprint patterns were recognized. Clusters varied
from two to nine isolates, with a median of 2.
We used a combination of IS6110-RFLP, spoligotyping,
and SCG for identiﬁcation of families of isolates. Not surpris-
ingly, the overall diversity of M. tuberculosis genotypes identi-
ﬁed in the Tula city clinic sample was higher than that in the
regional prison hospital [6]. However, the major families
were identical in both settings (Table 5). SCG3 was repre-
sented by a group of Haarlem isolates (19/30) and a number
of highly divergent strains in terms of their IS6110-RFLP pat-
terns (11/30). Although 16 of 34 SCG6 isolates shared the
ST53 spoligotype, the IS6110-RFLP showed a low level of
similarity between these strains. The Beijing strains (i.e.
those that shared spoligotype ST1: total number of isolates
70) and four Beijing-like isolates (ST1184) comprised the
SCG2. The Beijing strains contained two superclusters of
closely-related isolates: 13 (82% similarity) and 19 (70% simi-
larity). Ninety-three of 103 SCG5 isolates grouped together
on the IS6110-RFLP were members of LAM-RUS family, as
conﬁrmed by PCR [17]. A group of genotypes with overall
70% similarity seen on the IS6110-RFLP corresponded to
ST252 of LAM-RUS strains. This suggests relatively recent
clonal expansion of two Beijing strains and one LAM-RUS
strain in the population.
Identiﬁcation of IS6110 insertion in LAM-RUS strains
Members of the LAM-RUS family of strains show an easily
distinguishable ‘prototype’ pattern in IS6110-RFLP. In view of
the high prevalence and epidemiological relevance of the
LAM-RUS [17], we assumed that identiﬁcation of the stable
IS6110 insertion sites would help with respect to the inter-
laboratory tracking of strains. We used a modiﬁcation of
ligation-mediated PCR [13] for deciphering the IS6110-RFLP
pattern of the LAM-RUS. A total of 17 insertions were
identiﬁed in ﬁve clinical isolates. The major insertions are
summarized in Fig. 1. Because two regions of interest appear
to be deleted from the H37Rv genome, we followed the
numbering of the recently sequenced M. tuberculosis F11
strain (NC_009565). The presence of the ‘prototype’ inser-
tions was conﬁrmed by PCR in 20 LAM-RUS strains.
Of seven major insertions identiﬁed, three interrupted the
coding sequences, and four were located in the intergenic
regions. Four insertion sites were found near the sequences
coding for transposases conserved in M. tuberculosis H37Rv,
H37Ra, F11, and CDC1551 genomes.
Discussion
The resurgence of tuberculosis in recent decades in Russia
has been accompanied by dramatic increases in the preva-
lence of drug-resistant cases. Although reliable nationwide
surveillance data are not available [5], in some regions, the
primary MDR rate almost doubled, from 6.9% in 1998 to
13.5% in 2002 [18]. In the present study, the level of drug
resistance in new cases was almost two-fold higher than the
estimated average national level for this period (22% vs. 4–
13%) [19]. We speculated that this level was a result of the
epidemic spread of a limited number of highly-resistant
strains in the region. This assumption is supported by the
TABLE 5. Prevalence of major Mycobacterium tuberculosis
strain families in Tula region
Mycobacterium
tuberculosis strains
Civilian casesa
(n = 241)
Prison casesb
(n = 87) OR (95%CI)
Beijing and Beijing-like 73 (30%) 38 (44%) 0.6 (0.3–0.9)
LAM-RUS 93 (39%) 39 (45%) 0.8 (0.5–1.3)
Haarlem 19 (8%) 4 (5%) 1.7 (0.6–5.1)
Other 56 (23%) 6 (7%) 4.1 (1.7–9.6)
aPresent study.
bData from Ignatova et al. [6].
FIG. 1. IS6110 patterns of the LAM-RUS strains. Positions of inser-
tions are numbered according to Mycobacterium tuberculosis F11 (for
sequences, see Supporting Information). The ‘prototype’ pattern is
shown in bold. *Length may vary in different strains depending on
the spoligotype.
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strong association of MDR with IS6110-RFLP clustered iso-
lates (p <0.001). Approximately 70% of the civilian cases and
90% of prison cases in the region were a result of either
Beijing or LAM-RUS strains (Table 5). Surprisingly, the distri-
bution of these strains between new and previously treated
cases in the civilian population was disproportionate: new
cases accounted for 39.6% (23/58) of all Beijing strains and
only 14.5% (8/55) of ST252 LAM-RUS. This may reﬂect the
fact that Beijing strains are generally more transmissible,
whereas the treatment of patients infected with LAM-RUS
takes longer. The average time from diagnosis to the date of
specimen collection was almost twice as long in patients with
ST252 LAM-RUS (43.5 ± 9.4 months) compared to ST1 Beij-
ing (24.7 ± 7.8 month). Beijing strains are usually associated
with a high level of drug-resistant tuberculosis and outbreaks
[20,21]. This family of strains is highly prevalent in many Rus-
sian regions [22,23]. The Beijing family was also associated
with a high level of drug resistance in Tula: 25/58 (43.1%)
strains with ST1 were MDR. However, in contrast to the
other Russian regions, in our setting, the single LAM-RUS
strain was a major contributor to the MDR rate. All 55 iso-
lates with the predominant LAM-RUS ST252 spoligotype
were MDR, showed a high degree of similarity on IS6110
dendrogram and shared an identical list of mutations confer-
ring drug resistance, thus representing recent clones of a
unique MDR strain.
The history of incarceration is a widely recognized risk
factor for tuberculosis morbidity [24,25]. Prisons serve as
TB reservoirs, thus having a signiﬁcant impact on TB inci-
dence in the civilian population everywhere. However, the
actual links between these two settings are poorly docu-
mented. Individuals released from penitentiaries confront a
lack of money, work and legal residency issues, and face difﬁ-
culties with access to TB treatment. It was estimated that
less than 30% of released prisoners with active TB sought
treatment in civilian TB clinics [26]. Our previous study was
focused on TB patients in the Tula regional prison hospital
who were treated during the same time period, 2001–2002
[6]. Because we did not perform contact tracing, actual epi-
demiological links could not be established. Nevertheless,
molecular epidemiological data clearly showed the close links
between the civilian and prisoner populations in the Tula
region. Owing to prison conditions, highly transmissible
strains are more prevalent there than in the civilian setting.
Indeed, in the Tula prison hospital, 35/87 (40.2%) strains had
spoligotype ST1, which is characteristic of the highly trans-
missible Beijing family; however, in the civilians, only 58/234
(24.8%) had ST1. Moreover, in the present study, ex-prison-
ers were more infectious (i.e. had acid-fast positive smear;
p-value 0.0003). IS6110-RFLP clustering of isolates is
generally considered a marker for recent transmission chains.
Clustering cases were more prevalent in prisoners (54/87;
62.1%) and ex-prisoners (22/60; 36.7%) than in cases with no
history of previous incarceration (41/160; 25.6%). The aver-
age cluster size was larger in prison (4.5) than in civilian set-
tings (3.2). A combined dendrogram of IS6110-RFLP patterns
of isolates from prison and civilian settings revealed that all
major clusters (£8 isolates) were mixed (i.e. contained iso-
lates recovered from civilians and prisoners) (see Supporting
Information). For those civilians who were part of clusters,
the probability of being a part of the mixed cluster that
included prisoners was 0.33 (p 0.014). This probability is
likely to be higher given that the number of TB cases in
recently released prisoners is generally underestimated.
Molecular typing of the strains showed that the same ST252
LAM-RUS strain dominated in the prison hospital (27/87;
31%) [6], thus raising the question of the source of the out-
break.
The present study revealed that two major strains (i.e.
Beijing and LAM-RUS) were major contributors to the epi-
demic spread of TB in the region. However, their roles in
TB epidemiology were probably different: although Beijing
strains contributed to the incidence rate, LAM-RUS stains
were responsible for prevalence of MDR-TB. The epidemio-
logical situation in the region would beneﬁt from implemen-
tation of the DOTS plus approach supplemented with special
management of recently released prisoners with active
tuberculosis.
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